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Abstract
Background: Multidrug resistant tuberculosis (MDR-TB) is a serious public health problem in Nepal. It is a major
obstacle for the control of the tuberculosis. The main objectives of this study were to determine the prevalence of
the multidrug resistant pulmonary tuberculosis and to evaluate the drug susceptibility patterns of Mycobacterium
tuberculosis isolated from previously treated and newly diagnosed cases of pulmonary tuberculosis.
Methods: A cross-sectional study was conducted from March 2013 to August 2013 at German-Nepal tuberculosis
project (GENETUP) laboratory, Kathmandu, Nepal. For this the sputum samples from total of 153 (49 new and 104
previously treated) suspected pulmonary tuberculosis patients were used. The diagnosis of the tuberculosis was
performed by using fluorescent microscopy and culture, while the drug susceptibility testing of Mycobacterium
tuberculosis was performed by proportion method. Lowenstein-Jensen (L-J) medium was used for the culture of
Mycobacterium tuberculosis and the colonies grown were identified on the basis of the colony morphology,
pigment production and biochemical characteristics.
Results: The prevalence of MDR-TB among all the cases of culture positive pulmonary tuberculosis was 15.6 %. The
rate of MDR-TB among previously treated culture positive tuberculosis patients was 19.4 % and that among newly
diagnosed culture positive pulmonary tuberculosis cases was 7.1 %. The highest rate of resistance of Mycobacterium
tuberculosis, was toward streptomycin (24.4 %) followed by isoniazid (23 %), rifampicin (17.8 %) and ethambutol
(15.6 %). Among the total of MDR-TB cases among previously treated patients, highest percentage of the cases
were relapse (61.1 %) followed by chronic (16.7 %).
Conclusions: The high prevalence of DR/MDR-TB in our study reflects poor implementation of tuberculosis control
program. On the basis of the drug susceptibility patterns of M. tuberculosis we found in our study, we recommend
to include ethambutol instead of streptomycin in the multidrug therapy for the treatment of tuberculosis patients
in Nepal. Further, due to high rate of MDR-TB among previously treated patients, we do not recommend to use
first line drugs for the treatment of pulmonary tuberculosis among previously treated patients.
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Background
Tuberculosis (TB) is a communicable disease caused by
Mycobacterium tuberculosis. Primarily, the Mycobacter-
ium tuberculosis affects the lungs, causing pulmonary
tuberculosis (PTB) but it may also be involved in causing
extra pulmonary tuberculosis, in which sites of the body
other than lungs are affected. The common mode of
transmission of the tuberculosis is through droplet nu-
clei formed during coughing, sneezing, and speaking of
the patients suffering from pulmonary tuberculosis [1].
Tuberculosis is a global public health problem with a
worldwide incidence of 9 million TB cases, with 440,000
multidrug-resistant TB (MDR-TB) cases [2]. MDR-TB is
defined as the TB caused by strains of Mycobacterium
tuberculosis, which are resistant to two first-line drugs:
isoniazid and rifampicin [1].
The rate of death due to tuberculosis is highest in
Sub-Saharan Africa and Southeast Asia, and the majority
(99 %) of the death due to tuberculosis occurs in devel-
oping countries [3]. It has been estimated that every year
about 9 million new TB cases are diagnosed globally [4].
Worldwide, around 1.4 million deaths occurred in 2011
due to tuberculosis and according to World Health
Organization (WHO), if proper control measures are
not strengthened, by 2020 another 1 billion people will
be infected with around 36 million deaths [4].
In Nepal, about 45 % of the total population is infected
with Mycobacterium tuberculosis (both latent and active
infection) [5]. The rapid spread of HIV/AIDS and the re-
cent emergence of multidrug resistant (MDR) TB may
be responsible for worsening impact of tuberculosis and
increasing numbers of the tuberculosis cases [6].
The worldwide prevalence of the MDR-TB is esti-
mated to be 5 %; with 3.5 % of the new cases and 20.5 %
of the previously treated cases being MDR-TB [7]. The
neighboring countries, China and India are two coun-
tries with high TB burden, accounting for around one
third of the total TB cases in the world and have highest
MDR-TB rates [2, 7]. Recently, there have been reports
of increasing prevalence of MDR-TB [8]. The latest drug
resistance surveillance of 2011 in Nepal, found the
prevalence of MDR-TB to be 2.6 % and17.6 % among
new and previously treated cases respectively [6]. Re-
cently, the detection of MDR-TB in national surveillance
is more dependent on GeneXpert technology [9]. The
GeneXpert technology is a rapid and less labor intensive
method with low biohazard risk [10]. In contrast the
proportion method used in our study is time consuming,
more labor intensive (requiring skilled manpower) and
has high biohazard risk.
In this study, we determined the prevalence of the
multidrug resistant pulmonary tuberculosis and evalu-
ated the drug susceptibility patterns of Mycobacterium
tuberculosis isolated from previously treated and newly
diagnosed cases of pulmonary tuberculosis. This study
presented the more up to date information about the
prevalence of MDR-TB and drug susceptibility patterns
of Mycobacterium tuberculosis in Nepal.
Methods
Study design
A cross sectional descriptive study was carried out from
March 2013 to August 2013 at German-Nepal tubercu-
losis project (GENETUP) laboratory, Kathmandu, Nepal.
For this the sputum samples from total of 153 (49 new
and 104 previously treated) suspected pulmonary tubercu-
losis patients (having clinical and/or radiological features
of tuberculosis), received from all over Nepal were used.
The specimens which were culture negative and/or con-
taminated during culture were excluded from the study.
Sample collection
Three early morning sputum samples (per patient) were
collected in a sterile, leak proof, wide mouthed, transpar-
ent plastic container. Saliva and nasal secretions were
not accepted.
Microscopy
For microscopy auramine-phenol fluorochrome staining
was used [11].
Sputum culture for Mycobacterium tuberculosis
Method devised by Kent and Kubica was used for the di-
gestion, decontamination and concentration of sputum
samples [12]. For culture L-J medium was used. The col-
onies grown were identified on the basis of the colony
morphology, acid fast staining, pigment production and
biochemical characteristics [13].
Drug susceptibility testing by proportion method
Drug susceptibility testing of Mycobacterium tuberculosis
was performed by proportion method as suggested by
Heifets [14].
Quality control
For quality control, M. tuberculosis H37Rv was inocu-
lated into a series of drug containing media and control
media and incubated along with media inoculated with
the test strains.
Statistical analysis
Data were analyzed using statistical package for the so-
cial sciences (SPSS) version 16.0. The χ2 test was used
and p-value < 0.05 was considered statistically significant.
Results
Among the total of 153 patients, sputum samples from
129 patients were smear positive and those from 135
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patients were culture positive. Similarly, sputum samples
from 116 patients were both culture and smear positive.
Further, sputum samples from 19 patients were smear
negative but culture positive. In addition, samples from
five patients were both culture and smear negative.
Sputum samples from 13 patients were contaminated
during culture.
Case-wise distribution of PTB patients
Out of 135 Mycobacterium tuberculosis isolates, 31.1 %
(n = 42) isolates were isolated from new TB cases and
68.9 % (n = 93) isolates were isolated from the previously
treated TB cases. Among previously treated TB cases
the highest number of cases were relapse (59.1 %)
followed by treatment failure cases (15.1 %), chronic
cases (11.8 %), return after default cases (8.6 %) and
follow-up cases (5.4 %).
Drug susceptibility patterns of Mycobacterium tuberculosis
Of total 135 Mycobacterium tuberculosis isolates, 68.9 %
(n = 93) were sensitive to all four drugs and 31.1 %
(n = 42) were resistant to any drugs. The highest rate
of resistance was toward streptomycin (SM or S)
(24.4 %) followed by isoniazid (INH or H) (23 %), ri-
fampicin (RMP or R) (17.8 %) and ethambutol (EMB
or E) (15.6 %). Among the total of 135 culture posi-
tive TB cases, 21(15.6 %) were found to be MDR-TB.
The prevalence of MDR-TB (19.4 %) among the pre-
viously treated cases was significantly higher than that
among newly diagnosed cases (7.1 %) and the differ-
ence was statistically significant. Around 6.7 % of the
total culture positive TB cases were poly-resistant TB
(resistant to more than one drug but not MDR-TB).
No poly-resistant TB cases were reported among
newly diagnosed tuberculosis patients (Table 1).
Drug susceptibility patterns of Mycobacterium tuberculosis
isolated from different cases of previous treated patients
Among the total of MDR-TB cases among previously
treated patients, highest percentage of the cases were
relapse (61.1 %) followed by chronic cases (16.7 %),
treatment failure cases (11.1 %), return after default
cases (5.6 %) and follow-up cases (5.6 %). Drug suscepti-
bility patterns of Mycobacterium tuberculosis isolated
from different groups of previously treated patients are
presented in Table 2.
Discussion
Similar to our finding, Hajoj et al. in Saudi Arabia re-
ported the prevalence of MDR-TB among previously
treated TB patients to be 15.9 %, however they showed
lower rate of MDR-TB (in comparison to our study)
among newly diagnosed cases (1.8 %) [15]. Similarly,
Rijal et al. in their study during 2003 to 2004 found the
rates of MDR-TB among previous treated and new cases
to be 19.3 and 2.6 % respectively [16]. However, Subba
et al. reported quite high rate of MDR-TB cases (i.e.
22.2 % among new cases and 37.2 % among previously
treated cases) in a study during 2005 to 2006 [17]. Fur-
ther, during 2006 to 2007 Pradhan et al. discovered the
prevalence of MDR-TB to be 15.5 % among previously
treated cases and 4.2 % among new cases [18]. The most
recent drug resistance surveillance of 2011 in Nepal, re-
ported the prevalence of MDR-TB to be 2.6 and 17.6 %
among new and previously treated cases respectively [6].
Another study during 2011 to 2012 by Tharu et al. noted
the rate of MDR-TB among culture positive retreatment
cases to be 33 % [19]. A study conducted by Khunjeli et
al. in Nepal from 2012 to 2014 discovered the prevalence
of primary drug resistant tuberculosis to be 4.8 % [20].
The drug susceptibility patterns of M. tuberculosis iso-
lated in different studies conducted in Nepal during dif-
ferent periods of time have been presented in Table 3
[16–18, 21]. Over the years, there has been gradual in-
crease in primary MDR-TB in Nepal. This may be attrib-
uted to the increased rate of the acquired resistance,
which contributes to the rise in primary drug resistant
TB [6]. The main causes of high rates of drug resistance
among previously treated tuberculosis cases in Nepal
may be improper and/or incomplete treatment [22].
Table 1 Drug susceptibility patterns of Mycobacterium tuberculosis isolated from new and previously treated cases of pulmonary
tuberculosis
Susceptibility patterns Total cases (N = 135)
n (%)
New cases (N = 42)
n (%)
Previously treated cases (N = 93)
n (%)
Any drug resistance 42 (31.1) 9 (21.4) 33 (35.5)
Any isoniazid resistance 31 (23) 3 (7.1) 28 (30.1)
Any rifampicin resistance 24 (17.8) 4 (9.5) 20 (21.5)
Mono isoniazid resistance 2 (1.5) 0 2 (2.2)
Mono rifampicin resistance 2 (1.5) 1 (2.4) 1 (1.1)
MDR-TB 21 (15.6) 3 (7.1) 18 (19.4)
Poly-resistant TB (resistant to more
than one drug, but not MDR-TB)
9 (6.7) 0 9 (9.7)
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Other risk factors for development of MDR-TB are pre-
vious TB treatment, smoking habit, poverty, illiteracy,
migration to/from high MDR-TB prevalence areas, alco-
holism, poor housing, overcrowding and homelessness
[23, 24]. The mode of transmission of drug-resistant TB
is same as that of drug susceptible TB. And the trans-
mission of the MDR-TB is a very serious public health
issue, as it is very difficult to treat MDR-TB.
In accordance to our finding, in a study by Massi et
al., 60.9 % of the total M. tuberculosis isolates were
found to be sensitive to all four drugs, while 39.1 % of
the isolates were resistant to at least one of the four
drugs [25]. However, Pradhan et al. [18] and Rijal et al.
[16] noticed the rates of any drug resistance to be 52.5
and 67.8 % respectively.
Higher rate of sensitivity to RMP alone is a good indi-
cator for success of directly observed treatment short
course (DOTS) program but in our study 9.5 % of
mono-resistance to RMP was observed in new patients
showing the less success of the DOTS program in Nepal.
Similarly, in new cases mono-resistance to INH was
7.1 %. Pradhan et al. [18] showed the mono-resistance
among new cases to RMP and INH to be 4.2 and 1.4 %
respectively. Similarly, in a study by Rijal et al. [16]
mono-resistance among new cases to RMP and INH
were found to be 0 and 5.3 % respectively. Subba et al.
[17] also reported the mono-resistance among new cases
to RMP and INH to be 0 and 13.33 % respectively.
Green et al., reported 6.1 % resistance to RMP and
17.7 % resistance to INH from South Africa [26]. The
resistance of Mycobacterium tuberculosis to RMP and
INH is an alarming marker of MDR-TB [27]. As in
our study the mono-resistance to streptomycin was
reported to be highest in the studies by Pradhan et
al. [18] and Rijal et al. [16]. This may be explained by
the extensive use of streptomycin for the treatment of
other bacterial infections. The use of standard anti-
tubercular therapy in mono-DR-TB and poly-DR-TB
posses a great risk of treatment failure leading to the
development of MDR-TB in case of the mono-drug
and poly-drugs (non-MDR) resistant cases [26]. The
differences in the susceptibility patterns of M. tuber-
culosis in other countries and in Nepal, may be due to
the difference in effectiveness of tuberculosis control pro-
gram in different countries and difference in other risk
factors like previous TB treatment, improper and/or in-
complete treatment, smoking habit, poverty, illiteracy, mi-
gration to/from high MDR-TB prevalence areas,
alcoholism, poor housing, overcrowding and homelessness
in different countries. Further, difference in the frequently
used antibiotics from one country to another may also
contribute to difference in drug susceptibility patterns
among different countries.
Findings of our study suggest that relapse cases are
predominant over the other previously treated tubercu-
losis cases. Similar to our study, Al-Marri (85 %) in the
state of Qatar [28] and Subba et al. (68.4 %) in Nepal
[17] reported that the highest number of cases in previ-
ously treated TB patients were relapse.
The presence of DR/MDR-TB reflects poor tubercu-
losis control in the present or past which creates great
problem to effective implementation of TB control pro-
gram throughout the world [15]. So, for the effective im-
plementation of the TB control program, it is necessary
to have the laboratories where MDR-TB cases can be de-
tected but they are not sufficiently available in develop-
ing countries like Nepal [6]. In case of under developing
countries like Nepal, the rapid GeneXpert MTB/RIF
assay may be proved to be promising for detection of
MDR-TB cases. Early diagnosis, good quality treatment
under DOTS program, early screening and treatment in
closed contact and infection control program may be
very useful to improve health care service, hence to con-
trol the MDR-TB.
Table 2 Drug susceptibility patterns of Mycobacterium tuberculosis isolated from different groups of previously treated patients


















Any drug resistance 33 (35.5) 18 (32.7) 4 (28.6) 4 (50) 1 (20) 6 (54.6)
Any isoniazid resistance 28 (30.1) 16 (29.1) 2 (14.3) 3 (3.8) 1 (20) 6 (54.6)
Any rifampicin resistance 20 (21.5) 11 (20) 3 (21.4) 2 (25) 1 (20) 3 (27.3)
Mono isoniazid resistance 2 (2.2) 1 (1.8) 0 0 0 1 (9.1)
Mono rifampicin resistance 1 (1.1) 0 1 (7.1) 0 0 0
MDR-TB 18 (19.4) 11 (20) 2 (14.3) 1 (12.5) 1 (20) 3 (27.3)
Poly-resistant TB (resistant to more
than one drug, but not MDR-TB)
9 (9.7) 4 (7.3) 0 4 (50) 0 2 (18.2)
Note: Relapse cases are the patients who become symptomatic after completion of the treatment, treatment failure cases are the patients who remain smear
positive or culture positive even after 5 or more months of start of anti-tubercular therapy, default cases are the patients whose treatment is halted for at least
two consecutive months, follow up cases are the patients who are called in follow up even after successful completion of anti-tubercular therapy, chronic cases
are the patients who have received repeated incomplete treatment and who still have active tuberculosis that is considered to be incurable [6]
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Any drug resistance 9.8 % 0 13.2 % 28.6 % 11.0 % 40.9 % 36.8 % 75.2 % 64.5 % 74.8 % 46.5 % 67.2 % 4.7 % 25.3 % 21.4 % 35.5 %
Mono-drug resistance 5.7 % 0 7.6 % 11.6 % 7.0 % 13.0 % 23.7 % 32.3 % 20 % 23.6 % 24.3 % 25.9 % 9.1 % 6.1 % 14.3 % 6.5 %
Multidrug resistance 1.1 % 0 3.7 % 12.5 % 1.32 % 20.5 % 2.6 % 19.3 % 22.2 % 37.2 % 4.2 % 15.5 % 2.9 % 11.7 % 7.1 % 19.4 %
Resistance to all 4
first line drugs













DOTS can treat virtually all the patients with drug
susceptible TB [29]. And for the patients with MDR-TB,
DOTS Plus can be used for the treatment and to prevent
the development of the further drug resistance [30]. But
under DOTS Plus second-line injectable drugs, which
are inherently more toxic and less effective than first-
line drugs, are used daily for 2 years [30]. The treatment
is more expensive and prolonged. So it is necessary to
confirm MDR-TB (before starting treatment) in case of
failure of DOTS rather than presuming the patients fail-
ing DOTS to have MDR-TB and starting the 2nd line
anti-tubercular therapy [30].
Limitations of the study
Due to lack of resources, we could not include more
samples in our study. Multi-center studies including
large number of samples could have generated more sig-
nificant data. We could not use molecular methods for
the identification of the Mycobacterium tuberculosis.
Conclusions
In our study high rate of multidrug resistance was
noted. On the basis of the drug susceptibility patterns
of M. tuberculosis we found in our study, we recom-
mend to include ethambutol instead of streptomycin
in the multidrug therapy for the treatment of tuber-
culosis patients in Nepal. Further, due to high rate of
MDR-TB among previously treated patients, we do
not recommend to use first line drugs for the treat-
ment of pulmonary tuberculosis among previously
treated patients. The empiric treatment of tubercu-
losis should be based on the local drug susceptibility
patterns of M. tuberculosis. Rapid testing for drug re-
sistance by some methods like GeneXpert MTB/RIF
assay and improvement of infection control program
may be helpful in control of the tuberculosis.
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